The invention discloses a liver targeted
peptide-
recombinant human endostatin fusion protein, and a preparation method and application thereof. According to the invention, 19 amino acids in the N terminal conserved I region of plasmodium
circumsporozoite protein (CSP) capable of being specifically combined with
hepatocyte surface
receptor--
heparan sulfate proteoglycan (HSPG) are fused to the carboxyl terminal of a novel human
endostatin (nhES), the
amino terminal of which is added with 9
amino acid sequences (MGGSHHHHH), by a
gene engineering method, thereby obtaining the liver targeted
peptide-
recombinant human endostatin fusion protein (ES-CPS). The
fusion protein is easy to purify, can be specifically used in livers for inhibiting
neovascularization in a targeted mode, enhances the local concentration of the
medicine in the foci, reduces the consumption to the
whole body, and lowers the toxic or
side effect. The invention provides an idea and scientific reference for clinically developing medicines for treating liver cancers by targeted inhibition of
neovascularization, and has huge scientific meanings and practical value for further enhancing the
liver cancer treatment level in China.